Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04733755
Other study ID # C180201
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2018
Est. completion date September 1, 2018

Study information

Verified date January 2021
Source Pharmanex
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective is to evaluate the effects of oral supplement of a blend containing collagen peptides, phosphatidylserine, Saussurea involucrata and lutein (Beauty Image) on the improvement of skin aging in terms of hydration, gloss, melanin content, roughness and wrinkling, and anti-UV performance.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date September 1, 2018
Est. primary completion date August 1, 2018
Accepts healthy volunteers No
Gender All
Age group 28 Years to 55 Years
Eligibility Inclusion Criteria: - Facial skin with problems of dull, uneven, inelastic, dryness and wrinkle/fine line (At least fit to two problems) - In general good health and good mental state; - Willing to read, understand and able to sign the Informed Consent Form; - Willing to comply with all study protocol requirements. Exclusion Criteria: - Intention to become pregnant, pregnant, lactating or within 6 months of delivery; - Participation in any clinical test or cosmetic product test on skin within 30 days; - Existence of neurodermatitis, pityriasis, seborrheic dermatitis or psoriasis capitis on test area; - Use of any anti-inflammatory drugs in the past 2 months; - A history of skin diseases such as psoriasis, eczema, psoriasis, skin cancer, etc.; - IDDM: Insulin dependent diabetic patients; - Current treatment for asthma or other chronic respiratory diseases; - Undergoing anticancer chemotherapy in the past 6 months; - Existence of any other health problems or chronic diseases; - Use of retinoids, alpha hydroxyl acid, ortho-hydroxybenzoic acid, hydroquinone nearly within 3 months; or use of prescriptions (such as antibiotics, retinoids, alpha hydroxyl acid or steroids), oral contraceptives (Use of same contraceptives for 6 months excepted); - Existence of the following conditions or factors that the Investigator believes may affect the response of the skin or the interpretation of the test results, including, but not limited to, diabetes, vascular disease, hepatitis, eczema, psoriasis.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Beauty Image
1.97g/package; 2 packages one day for 8 weeks
Placebo Control
Placebo Control; 1.97g/package; 2 packages one day for 8 weeks

Locations

Country Name City State
China Nu Skin (China) Daily-use & Health Products CO., LTD Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Pharmanex

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in facial photo from baseline at week 4 and week 8 Facial Photo Capture by VISIA-CR CR (CANFIELD, America). The instrument captured all-face skin under different light sources about the Standard 1, Standard 2, UV light, Parallel-polarized light and Cross-polarized light source with left, front and right sides design. Baseline, Week 4 and Week 8
Primary Change in skin roughness from baseline at week 4 and week 8 Skin Roughness: VisioScan VC98 (Courage & Khazaka, Germany). The instrument consists of a special b/w video sensor chip with very high resolution, an objective and a ring shaped UVA-light source in a small, easy-to-handle, ergonomically designed plastic casing. The parameter of SEr (skin roughness) was analyzed in this study. Baseline, Week 4 and Week 8
Primary Change in skin wrinkle from baseline at week 4 and week 8 Skin Wrinkle: VisioScan VC98 (Courage & Khazaka, Germany) The instrument consists of a special b/w video sensor chip with very high resolution, an objective and a ring shaped UVA-light source in a small, easy-to-handle, ergonomically designed plastic casing. The parameter of SEw (wrinkles) was analyzed in this study. Baseline, Week 4 and Week 8.
Primary Change in skin color from baseline at week 4 and week 8 Skin Color of L, a, b and ITA: Spectrophotometer CM2600d (Konica Minolta, Japan) The Minolta spectrophotometer (Konica Minolta, CM2600d) is generally used to measure and carry out quality control of the color of an object. This instrument allows measurement in the modes of specular component included (SCI) and specular component excluded (SCE). As indicated by the description, SCI includes the specular reflection while SCE excludes the specular reflection from measured surface. The parameters of L, a, b value under SCE light source were recorded and the ITA value were calculated in this study. Baseline, Week 4 and Week 8
Primary Change in melanin content from baseline at week 4 and week 8 Melanin Content: Mexameter MX18 (Courage & Khazaka, Germany) The measurement is based on absorption/reflection. The probe of the Mexameter® MX 18 emits 3 specific light wavelengths. A receiver measures the light reflected by the skin. As the quantity of emitted light is defined, the quantity of light absorbed by the skin can be calculated. The melanin is measured by specific wavelengths chosen to correspond to different absorption rates by the pigments. For the erythema measurement specific wavelengths are also used, corresponding to the spectral absorption peak of haemoglobin and to avoid other color influences. Baseline, Week 4 and Week 8
Primary Change in skin gloss from baseline at week 4 and week 8 Skin Gloss: Glossymeter GL200 (Courage & Khazaka, Germany) The probe sends out white LED light, arranged circularly to uniformly illuminate the skin. The emitted light is scattered in all directions, some parts travel through the layers and some is scattered out of the skin. The light reflected from the skin is measured in the probe. The raw data of the probe are corrected with a special color matrix to adapt them closely to standard values and are expressed accordingly. Baseline, Week 4 and Week 8.
Primary Change in skin hydration from baseline at week 4 and week 8 Skin Hydration: Corneometer CM825 (Courage & Khazaka, Germany) It measures moisture content of the skin via capacitance measurements. The measurable capacitance is proportional to the water content of stratum corneum, given that other physical and physiological variables affecting skin electrical properties are carefully controlled. Baseline, Week 4 and Week 8.
Primary Change in transepidermal water Loss from baseline at week 4 and week 8 Transepidermal Water Loss (TEWL): Vapometer (Delfin Technologies, Finland) It's equipped with a closed cylindrical chamber. When it is in contact with the skin, the relative humidity (RH %) in the chamber increases, based on which transepidermal water loss (TEWL) is calculated. Lower TEWL means better skin barrier function. Vapometer measurement will be done at the tested areas on face skin. Baseline, Week 4 and Week 8.
Primary Change in skin elasticity from baseline at week 4 and week 8 Skin Elasticity: Cutometer dual MPA580 (Courage & Khazaka, Germany) The Cutometer® is destined to measure elasticity of the upper skin layer using negative pressure which deforms the skin mechanically. Baseline, Week 4 and Week 8.
Primary Change in anti-ultraviolet from baseline at week 4 and week 8 Evaluation of Anti-ultraviolet
Skin Carotenoid level was measured by NUSKIN S3 Biophotonic Scanner, this instrument measured on hand (the part of the hand between the thumb and the index finger).
The size and redness of sunburns were measured at 24hours after UV exposure with fixed light source and distance on back skin.
Baseline, Week 4 and Week 8.
Primary Change in dermatologist grading of skin tone dullness from baseline at week 4 and week 8 The skin parameter of skin tone dullness was assessed through '0 to 5' scales Baseline, Week 4 and Week 8.
Primary Change in dermatologist grading of skin tone unevenness from baseline at week 4 and week 8 The skin parameter of skin tone unevenness was assessed through '0 to 5' scales Baseline, Week 4 and Week 8.
Primary Change in dermatologist grading of skin dryness from baseline at week 4 and week 8 The skin parameter of skin dryness was assessed through '0 to 5' scales Baseline, Week 4 and Week 8.
Primary Change in dermatologist grading of skin inelastic from baseline at week 4 and week 8 The skin parameter of skin inelastic was assessed through '0 to 5' scales Baseline, Week 4 and Week 8.
Primary Change in dermatologist grading of wrinkle/fine line from baseline at week 4 and week 8 The skin parameter of wrinkle/fine line was assessed through '0 to 5' scales Baseline, Week 4 and Week 8.
Primary Change in dermatologist grading of skin roughness from baseline at week 4 and week 8 The skin parameter of skin roughness was assessed through '0 to 5' scales Baseline, Week 4 and Week 8.
Primary Self Assessment A self assessment questionnaire about skin conditions improvement was answered by each subject Baseline, Week 1, Week 2, Week 4 and Week 8.
See also
  Status Clinical Trial Phase
Completed NCT04276753 - A Randomized, Double-blinded, Placebo Controlled, Monocentric Study to Evaluate the Anti-ageing and Skin Brightening Benefit of the Test Product in Healthy Female Subjects N/A
Completed NCT06125912 - A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging N/A
Completed NCT02580370 - Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines Phase 3
Recruiting NCT01583478 - Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Phase 4
Completed NCT02003833 - Poly-L-lactic Acid for Skin Quality Phase 4
Completed NCT01447342 - A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines Phase 2/Phase 3
Completed NCT00986570 - Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face Phase 3
Completed NCT00974480 - Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging N/A
Completed NCT00272610 - Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin Phase 2
Recruiting NCT03730649 - Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure Early Phase 1
Completed NCT03312543 - Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles N/A
Active, not recruiting NCT05349799 - TEOSYAL RHA® 1 for Neck Lines, Perioral Lines and Smiling Lines N/A
Completed NCT03677258 - Effectiveness and Safety of Collagen Complex COLLOST in Anti-age Therapy N/A
Withdrawn NCT05854628 - The Role of Red Flavonoid in Photoaging N/A
Completed NCT01981980 - Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin Rejuvenation N/A
Not yet recruiting NCT00767156 - Effects of Oral and Topical Sea Buckthorn Oil Treatments on Skin Aging N/A
Recruiting NCT05813054 - Clinical Study to Evaluate the Anti-aging Efficacy of Dermial® N/A
Not yet recruiting NCT04485091 - TCA Peel and Photobiomodulation for Hand Rejuvenation Phase 2
Completed NCT05457491 - Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE) Phase 1
Completed NCT01237977 - Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines Phase 3